Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine

Livia Brusa, Antonio Orlacchio, Vincenzo Moschella, Cesare Iani, Giorgio Bernardi, Nicola Biagio Mercuri

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP's therapeutic use.

Original languageEnglish
Pages (from-to)126-129
Number of pages4
JournalMovement Disorders
Volume24
Issue number1
DOIs
Publication statusPublished - Jan 15 2009

Fingerprint

Tetrabenazine
Huntington Disease
Chorea
Therapeutics
Hyperkinesis
Dopamine D2 Receptors
Therapeutic Uses
Aripiprazole
Dopamine
Observation
Depression

Keywords

  • Aripiprazole
  • Huntington's disease
  • Neuroleptics
  • Tetrabenazine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Treatment of the symptoms of Huntington's disease : Preliminary results comparing aripiprazole and tetrabenazine. / Brusa, Livia; Orlacchio, Antonio; Moschella, Vincenzo; Iani, Cesare; Bernardi, Giorgio; Mercuri, Nicola Biagio.

In: Movement Disorders, Vol. 24, No. 1, 15.01.2009, p. 126-129.

Research output: Contribution to journalArticle

@article{54c0c418b5dd4098adf5458d63945c05,
title = "Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine",
abstract = "Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP's therapeutic use.",
keywords = "Aripiprazole, Huntington's disease, Neuroleptics, Tetrabenazine",
author = "Livia Brusa and Antonio Orlacchio and Vincenzo Moschella and Cesare Iani and Giorgio Bernardi and Mercuri, {Nicola Biagio}",
year = "2009",
month = "1",
day = "15",
doi = "10.1002/mds.22376",
language = "English",
volume = "24",
pages = "126--129",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment of the symptoms of Huntington's disease

T2 - Preliminary results comparing aripiprazole and tetrabenazine

AU - Brusa, Livia

AU - Orlacchio, Antonio

AU - Moschella, Vincenzo

AU - Iani, Cesare

AU - Bernardi, Giorgio

AU - Mercuri, Nicola Biagio

PY - 2009/1/15

Y1 - 2009/1/15

N2 - Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP's therapeutic use.

AB - Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP's therapeutic use.

KW - Aripiprazole

KW - Huntington's disease

KW - Neuroleptics

KW - Tetrabenazine

UR - http://www.scopus.com/inward/record.url?scp=61449249292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449249292&partnerID=8YFLogxK

U2 - 10.1002/mds.22376

DO - 10.1002/mds.22376

M3 - Article

C2 - 19170197

AN - SCOPUS:61449249292

VL - 24

SP - 126

EP - 129

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 1

ER -